News Sentiment

ENTX sentiment intelligence

Entera Bio Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.66 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +34.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 34.6% over four weeks
Fair value 1.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 30
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 7
Market source 6
GlobeNewswire 5
TradingKey 4
simplywall.st 3
Investing.com 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 16
Analyst action 4
Deals and strategy 1
Guidance 1
Regulatory and legal 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
TradingView Direct company coverage

After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion, highlighting the significant value placed on oral therapies for conditions traditionally treated by injections. Entera Bio is positioned to follow a similar path with its lead asset, EB613, an ora

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 13:13
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX

This article displays the "Price to earnings forward" value for Entera Bio Ltd. (NASDAQ: ENTX) as part of its financial overview on the TradingView platform. The information is presented without specific numerical data, indicating that the market was closed with no trades when th

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Entera Bio Ltd. – FWB:5DT

This page from TradingView provides financial information for Entera Bio Ltd. (FWB:5DT), specifically focusing on its price-to-earnings forward metric. The content includes an overview of the company's financials, news, community insights, forecasts, and seasonal data, noting tha

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Entera Bio Ltd. – FWB:5DT

This article provides a brief snapshot of the "Price to sales forward" value for Entera Bio Ltd. (FWB:5DT) on the Frankfurt Stock Exchange. It indicates that the market was closed at the time of viewing and no trades were recorded, while also listing various financial data source

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP

This page from TradingView provides financial information for Entera Bio Ltd. under the stock symbol A2JQXP on the Lang & Schwarz Exchange. It specifically highlights the enterprise value to EBIT forward metric for the company. The content appears to be a stub or a section of a l

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Entera Bio Ltd. – LSX:A2JQXP

The article focuses on the "Price to book forward" metric for Entera Bio Ltd. (LSX:A2JQXP), indicating a financial data point for the company. It appears to be a stub or a data point from a financial platform like TradingView, with no further detailed analysis provided.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 18:38
Source
TradingView
TradingView Direct company coverage

Entera Bio Ltd. Actuals & Estimates (HAM:5DT)

This article provides an overview of Entera Bio Ltd. (HAM:5DT) stock, including financial actuals and analyst estimates. It details the stock's future price forecast with a max and min estimate of 7.68 EUR, its historical highest and lowest prices, and key financial figures such

Tone
Positive 58/100
Event
Guidance
Published
26 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

ENTX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Entera Bio Ltd. (ENTX) stock, including a 1-year price target of $9.00 from one analyst. It details ENTX's recent price performance, market capitalization, earnings reports, and other financial metrics. The piece also addresses frequently aske

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP

This article provides financial information for Entera Bio Ltd. (LSX:A2JQXP) on TradingView, specifically focusing on its Price to Sales (forward) metric. It mentions the company's listing on the Lang & Schwarz Exchange under the Health Technology/Pharmaceuticals: Major sector. T

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 06:10
Source
TradingView
Market source Direct company coverage

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Bio Ltd. announced positive feedback from the FDA on its 12-month registrational Phase 3 study protocol for EB613, an oral anabolic tablet for postmenopausal women with osteoporosis. The FDA approved plans for a single randomized, double-blind, placebo-controlled trial wit

Tone
Positive 93/100
Event
Market update
Published
26 Jun 2026 00:12
Source
Market source
TradingView Direct company coverage

A2JQXP Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Entera Bio Ltd. (A2JQXP) stock for 2027, based on analyst opinions. It includes current stock price, market capitalization, volatility, and historical performance, alongside recent financial data like earnings and revenue. The

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 15:10
Source
TradingView
Investing.com Direct company coverage

H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback

H.C. Wainwright has reiterated a Buy rating and a $9.00 price target for Entera Bio (NASDAQ:ENTX) after the FDA accepted its Phase 3 registrational protocol for EB613, an oral osteoporosis treatment. Despite the stock surge following the announcement, an InvestingPro analysis ind

Tone
Positive 81/100
Event
Analyst action
Published
24 Jun 2026 11:40
Source
Investing.com
Stocktwits Direct company coverage

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

Entera Bio Ltd. (ENTX) shares surged over 52% after receiving positive feedback from the FDA regarding the design of its late-stage clinical trial for EB613, an experimental once-daily pill for postmenopausal osteoporosis. The FDA's backing for a single, large registrational tria

Tone
Positive 91/100
Event
Market update
Published
23 Jun 2026 09:10
Source
Stocktwits
Timothy Sykes Direct company coverage

ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline

Entera Bio Ltd. (ENTX) stock has seen a nearly 10% increase following positive clinical trial news showcased at ENDO 2026. The company presented strong preclinical data for EB612 and EB618, targeting hypoparathyroidism and obesity respectively, alongside Phase 1 data for its oral

Tone
Positive 76/100
Event
Market update
Published
22 Jun 2026 23:09
Source
Timothy Sykes
Stock Titan Direct company coverage

FDA backs Entera Bio’s 750-patient osteoporosis trial for EB613

Entera Bio received positive feedback from the FDA for its investigational drug EB613, an oral anabolic tablet designed for postmenopausal osteoporosis. The FDA approved a single 750-patient Phase 3 trial, with total hip BMD at 12 months as the primary endpoint, to support a New

Tone
Positive 74/100
Event
Regulatory and legal
Published
22 Jun 2026 14:40
Source
Stock Titan
TradingView Direct company coverage

With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For

Entera Bio received positive FDA feedback on the Phase 3 protocol for EB613, its oral PTH(1-34) tablet for postmenopausal osteoporosis. This significantly de-risks the development pathway for EB613, which aims to be the first oral anabolic treatment for osteoporosis, a market cur

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 13:09
Source
TradingView
TradingKey Direct company coverage

Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Entera Bio Ltd (ENTX), including its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the c

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 18:39
Source
TradingKey
TradingKey Direct company coverage

Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a brief overview of Entera Bio Ltd (ENTX) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock inform

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 17:09
Source
TradingKey
TradingKey Direct company coverage

Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Entera Bio Ltd (ENTX), noting its current valuation score of 6.71, which ranks it 300 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.58 and mentions that relevant data for P/B,

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:09
Source
TradingKey
TradingKey Direct company coverage

Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Entera Bio Ltd (ENTX) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $10.00 for ENTX, with one analyst giving it a "Buy" rating. The company's previous quarter's EPS was -$0.06, outperforming the market expec

Tone
Positive 76/100
Event
Earnings
Published
18 Jun 2026 01:41
Source
TradingKey
Investing.com South Africa Direct company coverage

Entera Bio reports preclinical data for two oral peptide programs By Investing.com

Entera Bio Ltd. (NASDAQ:ENTX) presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs, co-developed with OPKO Health Inc., utilize Entera's N-Tab oral peptide platfo

Tone
Positive 67/100
Event
Market update
Published
17 Jun 2026 07:40
Source
Investing.com South Africa
Sahm Direct company coverage

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Entera Bio Ltd. announced robust preclinical data for its oral peptide programs, EB612 and EB618, at ENDO 2026. EB612, an oral long-acting PTH(1-34) for hypoparathyroidism, demonstrated strong bioavailability and sustained calcium increases in preclinical models, with an IND fili

Tone
Positive 75/100
Event
Market update
Published
16 Jun 2026 19:40
Source
Sahm
Investing.com Direct company coverage

Entera Bio reports preclinical data for two oral peptide programs

Entera Bio Ltd. presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs utilize the company's N-Tab oral peptide platform technology and are co-developed with OPKO H

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 18:09
Source
Investing.com
Stock Titan Direct company coverage

Experimental oral hormone pills aim at hypoparathyroidism, obesity

Entera Bio (NASDAQ: ENTX) presented robust preclinical data for its oral drug candidates EB612 and EB618 at ENDO 2026. EB612, for hypoparathyroidism, demonstrated sustained calcium restoration in preclinical models, with an IND filing targeted for late 2026. EB618, for obesity an

Tone
Positive 62/100
Event
Market update
Published
16 Jun 2026 12:10
Source
Stock Titan
Stock Titan Direct company coverage

ENTX SEC Filings - Entera Bio Ltd 10-K, 10-Q, 8-K Forms

This page on StockTitan.net provides comprehensive access to Entera Bio Ltd. (ENTX) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors monitoring the Nasdaq-listed clinical-stage biopharmaceutical company. The filings cover financial results, regulatory updat

Tone
Positive 61/100
Event
Earnings
Published
16 Jun 2026 07:10
Source
Stock Titan